Startups
HuntX Pharma
Grenoble / La Tronche, France
HuntX Pharma is a French neuroscience biotechnology company founded in December 2022 by Laure Jamot and Frédéric Saudou. It develops small-molecule therapies for neurological diseases involving impaired axonal transport. Its first candidate, HX127, targets Huntington’s disease and aims to restore transport of brain-derived neurotrophic factor between neuronal regions. The company uses microfluidic brain-on-a-chip models and imaging to identify compounds; an AI platform is not inferred. Published efficacy statements concern developer-reported preclinical models, rather than established clinical benefit or an approved treatment. Its 2024 release planned regulatory animal studies and a future 2026 Phase 1 trial; current completion is unverified. The website’s legal owner is SAS HuntX Pharma, SIREN 921853990, with research contacts in Grenoble/La Tronche. It announced EUR 1.7M raised on September 19, 2024 from Angels Santé, Paris Business Angels, Grenoble Angels and unnamed patient families. These network attributions represent members or syndicates, not proof of association treasury allocations. SATT Linksium is separately named as an incubator and existing shareholder. Bpifrance/France 2030 support and Ipsen’s 2024 Golden Ticket are qualified separately from priced equity financing.
Founded 2022
Team
 Frédéric SaudouChief Scientific Officer · Cofounder |
 Laure JamotPresident · Cofounder |